Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,095.60
(
-0.42%
)
Dow Jones
49,490.03
(
0.00%
)
Brent Oil
97.88
(
1.19%
)
Bitcoin
77,672.40
(
-0.72%
)
News Focus
News Focus
Post# of 44698
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Inelgr

Send PM Follow Ignore
Followers 5
Posts 91
Boards Moderated 0
Alias Born 08/11/2020

Inelgr

Re: PennyWorld post# 27747

Friday, 10/23/2020 10:45:01 PM

Friday, October 23, 2020 10:45:01 PM

Post# of 44698
In post 27700, you stated:

RLF-100 targets the lungs and the VPAC1 receptor (which is tied to COVID19). The other failed drug (from PhaseBIO) targets the blood vessels (VPAC2 receptor) and treating high blood pressure



As stated in post 27731, according to the Relief Therapeutics website, - it activates BOTH the VPAC1 and VPAc2 receptors (not "just" VPAC1).
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent RLFTF News
More RLFTF News